Immunotherapy

The immune system can recognise abnormal cells. Cancers sometimes switch that recognition off by using checkpoints, which are normal brakes on immune cells. Checkpoint inhibitors release those brakes. The result, when it works, is that immune cells attack the cancer. The same release can make immune cells attack healthy organs. That is why the side effects look like inflammation rather than like classic chemotherapy effects, and why they can appear in the skin, bowel, liver, lung, joints, or hormone glands.

Other immune treatments exist, including some antibodies that flag a target on the cancer cell, and cellular therapies used in specialist centres for selected blood cancers. Those are not what most people mean when a lung, kidney, or bladder cancer consultation mentions immunotherapy. Ask which kind is being discussed. The monitoring and the risks are not the same.

Common settings include selected lung cancers, kidney cancers, melanomas, some bladder cancers, some triple-negative breast cancers, some lymphomas, and a smaller set of tumours with a matching biomarker such as high MSI. The cancer type, the stage, and prior treatment matter as much as the drug name. A consultation looks at whether evidence supports immunotherapy for that situation. The fact that the drug is newer is not evidence.

Biomarkers help in some diseases and are irrelevant in others. PD-L1 is often checked in lung cancer. MSI or mismatch-repair testing matters in several cancers when immunotherapy is otherwise not standard. A high PD-L1 does not guarantee a response, and a low result does not always rule treatment out. Autoimmune disease, an organ transplant, or the need for steroids for another illness can make immunotherapy a poor or unsafe choice. Those conditions should be on the medicine list you bring.

Most checkpoint inhibitors are infusions every few weeks. Some are combined with chemotherapy on the same day, and some with a targeted drug. A course may continue for a defined period or until the cancer grows or side effects require a stop. Blood tests before each dose look at the liver, thyroid, kidneys, and counts. You may feel well enough to drive and to work. That does not mean the treatment is inactive, and it does not mean side effects cannot appear suddenly.

Response on scans can be slower than with chemotherapy, and occasionally a tumour looks briefly larger because immune cells have entered it. That pattern is interpreted carefully. It is not a reason for a patient to decide the drug is failing, and it is not a reason to ignore clear growth. The oncologist compares symptoms, blood tests, and the scan together before calling a treatment a success or a failure.

Diarrhoea, severe fatigue, a new cough or breathlessness, yellow skin, a widespread rash, severe headache, or unusual thirst and passing large amounts of urine can be immune-related. They may start during treatment or, less often, after it has stopped. Report them quickly. Mild itch or a small rash may be manageable with clinic advice. Do not start steroid tablets that you have at home, and do not stop the cancer drug, without speaking to the treating team. Steroids are the usual antidote for serious immune side effects, and they have to be dosed and tapered correctly.

• Bowel: diarrhoea, blood, or pain that is new
• Lung: cough or breathlessness that is not a simple cold
• Liver: jaundice, dark urine, or abnormal blood tests you may not feel
• Hormones: profound tiredness, headache, dizziness, or changes in thirst
• Skin: a rash that spreads, blisters, or involves the mouth

Some immune effects on hormone glands are permanent and need replacement tablets, such as thyroid hormone, even after the cancer drug has stopped. That is manageable and it is a reason for blood tests to continue. Infection can look like an immune side effect. The team may need to exclude infection before giving steroids. A fever still needs assessment. It is not automatically an immune event and it is not automatically safe to watch at home.

It does not work for every cancer, and it does not work for every person who receives it. Some cancers grow despite treatment. Combining it with chemotherapy can add the side effects of both. It is not a vitamin, a vaccine you can buy, or a diet. Products sold as immune boosters can interfere with treatment or with the blood tests used to keep you safe. Bring them up before you start them.

It is also not automatically safer than chemotherapy. Some people tolerate immunotherapy well for a long time. Others develop serious inflammation that needs hospital care. The safer choice is the one that fits the cancer and the person’s other illnesses. Feeling that immune treatment sounds more natural is not a clinical reason to choose it.

Ask what the treatment is aiming to do, how you will know it is working, and which symptoms should interrupt daily life. Ask about fertility, pregnancy, and vaccines. Inactivated vaccines are often acceptable. Live vaccines are usually avoided. The timing of a flu or COVID vaccine can usually be planned around infusions. Tell the clinic about tuberculosis history, hepatitis, and any steroid or immunosuppressive medicine. People planning dental work or surgery should mention the immunotherapy, because healing and infection risk can matter.

Carry a short note that you are on immunotherapy, in case you attend another hospital with diarrhoea or breathlessness. Other clinicians may not connect those symptoms to the drug unless they are told. Follow-up continues after the last dose because side effects can be delayed. A clear scan is welcome. It is not the moment to disappear if blood tests were still being watched.

Bring the pathology, PD-L1 or MSI result if it exists, a list of autoimmune conditions, and every steroid or immunosuppressive medicine. Mention thyroid disease, inflammatory bowel disease, and previous tuberculosis or hepatitis. These do not always forbid immunotherapy. They change how closely you are watched and sometimes whether the drug is wise at all. Write down cough, diarrhoea, or rash you already have, so new symptoms later can be compared with your baseline.

Ask why immunotherapy is being chosen instead of, or together with, chemotherapy. Ask which organs’ side effects you must report, how soon steroids would be used, and how long blood tests continue after the last dose. Ask for a wallet card or a written line you can show another hospital. Immune side effects are treatable mainly when they are recognised early. The preparation is part of the safety of the drug, not paperwork beside it.

A visit about immunotherapy is used to read the records you already have, explain them in plain language, and outline options that may apply. Bring the biopsy or pathology report, scan CDs or reports, blood tests, and a list of treatment already given, including dates and drug names if you have them. A family member can come with you. The visit is not an emergency assessment, and it does not confirm a plan until the records have been reviewed.

Dr. Nishith Vaddeboina is a medical oncologist. Appointments published on this website are at American Oncology Institute, Nallagandla, Hyderabad. The biography also lists consultant work at Renova Century Hospitals. Confirm the hospital when you book. Plans are discussed against recognised guidance, including NCCN, ESMO, and ASCO, and then adjusted to the person in the room. Nothing on this page replaces that conversation.